TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00404378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: Ketoconazole tablets will be available with dose strength of 200 mg. The dose of ketoconazole 400 mg will be comprised of two 200 mg tablets. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: Ketoconazole tablets will be available with dose strength of 200 mg. The dose of ketoconazole 400 mg will be comprised of two 200 mg tablets. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casopitant 100 mg
Description: Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive two 50 mg tablets for the dose of 100 mg. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casopitant 100 mg
Description: Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive two 50 mg tablets for the dose of 100 mg. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant 50 mg
Description: Casopitant tablets will be available with dose strength of 50 mg and will receive single dose. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant 50 mg
Description: Casopitant tablets will be available with dose strength of 50 mg and will receive single dose. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.
Study: NCT01221753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study: NCT01081678

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous (under the skin) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection
Study: NCT01112865

Intervention type: DEVICE
Group type: OTHER
Intervention: Genotropin Pen
Description: Pen provided in 5, 5.3 and 12 mg doses, Dose based on body weight, subcutaneous injection daily for 2 months while in study.

Intervention type: DEVICE
Group type: OTHER
Intervention: MARK VII pen
Description: Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.

Intervention type: DEVICE
Group type: OTHER
Intervention: Genotropin Pen
Description: Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.

Intervention type: DEVICE
Group type: OTHER
Intervention: MARK VII pen
Description: Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
Study: NCT01830270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 8 weekly cycles of chemotherapy with epirubicin (50 mg/m2)associated with cisplatin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 8 weekly cycles of chemotherapy with cisplatin (30 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 8 weekly cycles of chemotherapy with paclitaxel (90 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric surgery
Description: surgery will be scheduled within 4-6 weeks after the end of the last cycle of chemotherapy.
Study: NCT00378378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate Nasal Spray (MFNS)
Description: 100 mcg nasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate Nasal Spray (MFNS)
Description: 100 mcg nasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate Nasal Spray (MFNS)
Description: 100 mcg nasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate Nasal Spray (MFNS)
Description: 100 mcg nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: One spray of placebo nasal spray in each nostril once daily for 4 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: One spray of placebo nasal spray in each nostril once daily for 4 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: One spray of placebo nasal spray in each nostril once daily for 4 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: One spray of placebo nasal spray in each nostril once daily for 4 months.
Study: NCT01221753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given intravenously on day 1 of each cycle
Study: NCT02031068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Rehabilitation Program
Description: The active rehabilitation program will be implemented for a maximum of 6-8 weeks. Each participant will be followed by regular weekly telephone calls or personal follow-up relating to outcome from concussion and managing symptoms. The participant will receive TAU (above) in addition to the 4 components listed below:~1. Sub-maximal aerobic training for up to 15 minutes~2. Light coordination and sport-specific exercises for up to 10 minutes~3. Visualization and imagery techniques~4. Home program~A physiotherapist will supervise the rehabilitation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual (TAU)
Description: The TAU program will be implemented after the initial assessment. It will consist of 2 components:~An initial education session by an occupational therapist, relating to outcome from concussion and managing symptoms A school consultation to provide teacher education, recommend accommodations, and facilitate return to school
Study: NCT03288441

Intervention type: BIOLOGICAL
Intervention: Change platelet transfusion threshold
Description: Increase or reduce platelet transfusion threshold

Intervention type: DRUG
Intervention: Full dose antithrombotics
Description: Continue full dose antithrombotic therapy

Intervention type: DRUG
Intervention: Full dose antithrombotics
Description: Continue full dose antithrombotic therapy

Intervention type: DEVICE
Intervention: Mechanical measures
Description: Mechanical measures to reduce thrombotic risk including: IVC filter insertion, Intermittent Pneumatic Compression (IPC), Removal of Central venous catheter

Intervention type: DRUG
Intervention: Intermediate dose antithrombotic
Description: Reduction in antithrombotic medication dose to prophylactic dose (without changing type). Intermediate dose in between prophylactic and full dose
Study: NCT00838370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, 5-fluorouracil
Description: Patients to treat with capecitabine/5-FU will be screened prior to start of therapy for DPYD\*2A. Patients heterozygous or homozygous mutant for DPYD\*2A receive dose reductions of capecitabine/5-FU of at least 50% in the first two courses. In case this dose is tolerated well, doses will be increased.~In addition, the pharmacokinetics of capecitabine/5-FU and their metabolites will be assessed in these patients.
Study: NCT01221753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study: NCT01095991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Oral tablet bd,
Study: NCT01614041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual dose treatment of Tandospirone
Description: Usual dose treatment of Tandospirone, oral, 30 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparative high dose of tandospirone treatment
Description: Comparative high dose of tandospirone treatment, oral, 60 mg/day
Study: NCT01363258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care-resistant mouth care (MOUTh)
Description: The intervention combines best mouth care practices with a constellation of behavioral techniques that reduce threat perception and thereby prevent or de-escalate care-resistant behavior.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Evidence-based mouth care
Description: Mouth care tailored to the needs of older adults, including care of dentures.
Study: NCT02178306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan high dose
Description: patients switch to high dose if mean SBP \>= 85 mmHg after 4 weeks of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Run-in phase
Study: NCT01548170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: One capsule of sunitinib 50 mg orally. Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib and Ketoconazol
Description: Sunitinib capsule 37.5mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
Study: NCT03381911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embodied Conversational Agent
Description: The Embodied Conversational Agent (ECA) is a computer generated character that can interact with study subjects through a touch screen computer. The ECA is programmed to respond with relevant speech and body language to a subject's responses.
Study: NCT03799081

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fetoscopy
Description: Fetoscopy is a procedure that enables viewing of the fetus through use of a hysteroscope
Study: NCT02076334

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Far Infrared Fabric

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Far Infrared Fabric

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Far Infrared Fabric

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spandex

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spandex

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Spandex
Study: NCT03713424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clavulanic Acid
Description: Beta lactamase inhibitor for smoking cessation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: placebo
Study: NCT02180490

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UHAC 62 XX tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHAC 62 XX tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UHAC 62 XX capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHAC 62 XX capsule
Study: NCT00716326

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Nerve Stimulation (TENS)
Description: Patients will be randomly allocated to a group with active-TENS and exercises, or to a group with placebo-TENS and exercises. The TENS will be used during 3-4 weeks of hospitalization. If patients want to continue the use of TENS/placebo-TENS at home, they will be offered to borrow equipment for 4 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cefar Primo Pro TENS device
Description: Patients will be randomly allocated to a group with active-TENS and exercises, or to a group with placebo-TENS and exercises.~Active TENS: high-frequency modulated pulse duration stimulation Placebo TENS: manipulated device with impulses near sensory threshold.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cefar Primo Pro TENS device
Description: Patients will be randomly allocated to a group with active-TENS and exercises, or to a group with placebo-TENS and exercises.~Active TENS: high-frequency modulated pulse duration stimulation Placebo TENS: manipulated device with impulses near sensory threshold.
Study: NCT01548170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitiinb and Ketoconazol
Description: Sunitinib capsule 37.5mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib and Ketoconazol
Description: Sunitinib capsule 25mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib and Ketoconazol
Description: Sunitinib capsule 25mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
Study: NCT02989311

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified maize porridge (MNP and Iron)
Description: Maize porridge fortified with MNP and labelled iron compound
Study: NCT00727636

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil vaccine
Description: standard 0.5 mL dose of Gardasil vaccine given at Day 0, Month 2, and Month 6
Study: NCT01333254

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent urinary catheterisation
Description: Patients randomised to the I group will urinate either in a toilet or in a bedpan or a diaper when needed. Bladder scan control will be performed on these patients at least every four hour. If the patient is unable to urinate and bladder scan indicates ≥ 450 ml urine in the bladder, the patient will be intermittent catheterised.
Study: NCT02231944

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Replenine®-VF (High Purity Factor IX)
Study: NCT00289991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole
Description: Prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vfend - voriconazole
Description: Prophylaxis
Study: NCT02249585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard abdominal pressure
Description: Abdominal pressure maintained 12mmHg throughout laparoscopic colon surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard abdominal pressure
Description: Abdominal pressure maintained 12mmHg throughout laparoscopic colon surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low abdominal pressure
Description: Abdominal pressure maintained 8mmHg throughout laparoscopic colon surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional neuromuscular blockade
Description: Anesthesia induction with rocuronium 0.4mg/kg and maintenance with rocuronium 0.15mg/kg to maintain TOF 1-2 twitch
Study: NCT01095991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Oral tablet bd,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Oral tablet od

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Oral tablet od
Study: NCT00050557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifamily Psychoeducation Group (MFPG)
Description: MFPG will include 8 weekly 90-minute group therapy sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multifamily Psychoeducation Group (MFPG)
Description: MFPG will include 8 weekly 90-minute group therapy sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: Participants will receive standard care for mood disorders.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Participants will receive standard care for mood disorders.
Study: NCT01591954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video Augmentation
Description: Assessment of value of video-based navigation system
Study: NCT02989311

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified maize porridge (MNP and Iron)
Description: Maize porridge fortified with MNP and labelled iron compound

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified Maize porridge (MNP + Iron + GOS)
Description: Maize porridge fortified with MNP + GOS and labelled iron compound

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified Maize porridge (MNP + Iron + GOS)
Description: Maize porridge fortified with MNP + GOS and labelled iron compound
Study: NCT01917240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Chromosome Screening
Description: On day 5 or 6 of embryo development, all embryos will undergo a trophectoderm biopsy using the standardized technique, as according to standard laboratory protocol and without regard to study. Comprehensive Chromosome Screening (CCS) results will be available by the morning of day 6 if embryos are suitable for a fresh transfer which is the routine in our program.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Comprehensive Chromosome Screening
Description: On day 5 or 6 of embryo development, all embryos will undergo a trophectoderm biopsy using the standardized technique, as according to standard laboratory protocol and without regard to study. Comprehensive Chromosome Screening (CCS) results will be available by the morning of day 6 if embryos are suitable for a fresh transfer which is the routine in our program.
Study: NCT01781663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KAM2904 Face Cream

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KAM3008 Body Lotion
Study: NCT02249585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade
Description: Anesthesia induction with rocuronium 0.8mg/kg → maintenance with rocuronium 0.3mg/kg to maintain PTC 1-2 twitch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade
Description: Anesthesia induction with rocuronium 0.8mg/kg → maintenance with rocuronium 0.3mg/kg to maintain PTC 1-2 twitch
Study: NCT01781663

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: petrolatum-based moisturizer
Study: NCT03717116

Intervention type: DIAGNOSTIC_TEST
Intervention: parathormone level
Description: From the patients, blood will be taken preoperatively and postoperatively.

Intervention type: DIAGNOSTIC_TEST
Intervention: parathormone level
Description: From the patients, blood will be taken preoperatively and postoperatively.
Study: NCT02999815

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Human tetanus immunoglobulin
Description: Adults admitted to ICU at Hospital for Tropical Diseases will be randomized to receive either human (3000 IU) or equine (21,000 units) intramuscular antitoxin. Second, participants will be randomized to receive the addition of 500 IU intrathecal human antitoxin.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Human tetanus immunoglobulin
Description: Adults admitted to ICU at Hospital for Tropical Diseases will be randomized to receive either human (3000 IU) or equine (21,000 units) intramuscular antitoxin. Second, participants will be randomized to receive the addition of 500 IU intrathecal human antitoxin.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Intramuscular antitoxin
Description: First, adults admitted to ICU at Hospital for Tropical Diseases will be randomized to receive either human (3000 IU) or equine (21,000 units) intramuscular antitoxin including a 0.05ml test dose (ie 75 units equine antitoxin or 12.5 IU human antitoxin). Second, participants will be randomized with sham procedure
Study: NCT03314012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter-Based Carotid Body Ablation
Description: The Cibiem Transvenous Ultrasound System (CTUS) is a catheter based device delivering ultrasound energy to ablate the carotid body. The procedure is done via a percutaneous insertion of the CTUS and advancement through the femoral vein to the jugular vein in subjects with difficult to control hypertension. The procedure duration is expected to range between 60 to 90 minutes and is performed under fluoroscopic and ultrasound image guidance.
Study: NCT03125993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: >10000 steps brisk walking
Description: This study is a prospective 4-month follow-up scheme in which patients were treated with the following intervention: \> 10000 steps, \> five days, per week brisk walking.
Study: NCT03125161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAI
Description: HAI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy ± target therapy
Description: chemotherapy ± target therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy ± target therapy
Description: chemotherapy ± target therapy
Study: NCT02318069

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FSME-immune
Description: 0.5 ml im as scheduled in the 5 arms
Study: NCT03363191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Vilanterol
Description: Fluticasone furoate/vilanterol will be supplied as inhalation powder in ELLIPTA DPI. It will contain 2 strips with 30 blisters per strip. First strip will contain fluticasone furoate 100 mcg dry white powder blended with lactose. Second strip will contain vilanterol 25 mcg dry white powder blended with lactose and magnesium stearate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate
Description: Fluticasone furoate will be supplied as inhalation powder in ELLIPTA DPI. It will contain a single strip with 30 blisters, containing fluticasone furoate 100 mcg dry white powder blended with lactose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol/Albuterol
Description: Salbutamol/albuterol will be provided to subjects to use as rescue medication on an as-needed basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol/Albuterol
Description: Salbutamol/albuterol will be provided to subjects to use as rescue medication on an as-needed basis.
Study: NCT03789123

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Estradiol valerate/dienogest
Description: The effects of drugs given for endometrioma and contraception will be observed on ovarian reserve, endometrioma size and pain score.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol valerate/dienogest
Description: The effects of drugs given for endometrioma and contraception will be observed on ovarian reserve, endometrioma size and pain score.